Compare AIN & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | AMPH |
|---|---|---|
| Founded | 1895 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1987 | 2014 |
| Metric | AIN | AMPH |
|---|---|---|
| Price | $56.58 | $28.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $60.25 | $31.00 |
| AVG Volume (30 Days) | 286.8K | ★ 329.4K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.27 |
| Revenue | ★ $1,148,512,000.00 | $723,305,000.00 |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $4.84 |
| P/E Ratio | ★ N/A | $12.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $41.15 | $20.39 |
| 52 Week High | $83.65 | $34.39 |
| Indicator | AIN | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 64.38 |
| Support Level | $54.61 | $25.80 |
| Resistance Level | $57.21 | $26.71 |
| Average True Range (ATR) | 1.52 | 0.94 |
| MACD | -0.34 | 0.21 |
| Stochastic Oscillator | 40.91 | 86.33 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.